

# Jay A Berzofsky

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2558464/publications.pdf>

Version: 2024-02-01

239  
papers

20,129  
citations

10650

74  
h-index

13635

134  
g-index

241  
all docs

241  
docs citations

241  
times ranked

21522  
citing authors

#	ARTICLE	IF	CITATIONS
1	MPAPASS software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays. <i>Cell Reports Methods</i> , 2022, 2, 100136.	1.4	8
2	BepiTBR: T-B reciprocity enhances B cell epitope prediction. <i>IScience</i> , 2022, 25, 103764.	1.9	9
3	The role of NKT cells in gastrointestinal cancers. <i>Oncolimmunology</i> , 2022, 11, .	2.1	6
4	An intranasally administrated SARS-CoV-2 beta variant subunit booster vaccine prevents beta variant replication in rhesus macaques. , 2022, 1, .		10
5	Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy. <i>Cancer Letters</i> , 2021, 499, 279-289.	3.2	7
6	The Role of CXCL13 in Antibody Responses to HIV-1 Infection and Vaccination. <i>Frontiers in Immunology</i> , 2021, 12, 638872.	2.2	14
7	Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques. <i>JCI Insight</i> , 2021, 6, .	2.3	52
8	SARS-CoV-2 Spike Protein Suppresses ACE2 and Type I Interferon Expression in Primary Cells From Macaque Lung Bronchoalveolar Lavage. <i>Frontiers in Immunology</i> , 2021, 12, 658428.	2.2	30
9	A simple, high-throughput method of protein and label removal from extracellular vesicle samples. <i>Nanoscale</i> , 2021, 13, 3737-3745.	2.8	6
10	Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization. <i>Pathogens</i> , 2021, 10, 138.	1.2	60
11	Unique challenges for glioblastoma immunotherapyâ€”discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. <i>Neuro-Oncology</i> , 2021, 23, 356-375.	0.6	59
12	Undetectable Anti-HBs Antibodies: Need of a Booster Dose for HIV-1-Infected Individuals. <i>Vaccines</i> , 2021, 9, 1484.	2.1	1
13	Thomas Alexander Waldmann. <i>Immunity</i> , 2021, 54, 2671-2672.	6.6	0
14	Complementary approaches to study NKT cells in cancer. <i>Methods in Enzymology</i> , 2020, 631, 371-389.	0.4	1
15	High Sensitivity Protein Gel Electrophoresis Label Compatible with Mass-Spectrometry. <i>Biosensors</i> , 2020, 10, 160.	2.3	4
16	Diversity Outbred Mice Reveal the Quantitative Trait Locus and Regulatory Cells of HER2 Immunity. <i>Journal of Immunology</i> , 2020, 205, 1554-1563.	0.4	8
17	A Prime/Boost Vaccine Regimen Alters the Rectal Microbiome and Impacts Immune Responses and Viremia Control Post-Simian Immunodeficiency Virus Infection in Male and Female Rhesus Macaques. <i>Journal of Virology</i> , 2020, 94, .	1.5	7
18	Myeloid Cell-Mediated Trained Innate Immunity in Mucosal AIDS Vaccine Development. <i>Frontiers in Immunology</i> , 2020, 11, 315.	2.2	14

#	ARTICLE	IF	CITATIONS
19	Synthetic preparation and immunological evaluation of $\hat{I}^2$ -mannosylceramide and related N-acyl analogues. <i>Organic and Biomolecular Chemistry</i> , 2020, 18, 2739-2746.	1.5	2
20	Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus. <i>Journal of Clinical Investigation</i> , 2020, 130, 2789-2799.	3.9	26
21	Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory. <i>Oncolmunology</i> , 2019, 8, e1625687.	2.1	9
22	Structure-Function Implications of the Ability of Monoclonal Antibodies Against $\hat{I}^{\pm}$ -Galactosylceramide-CD1d Complex to Recognize $\hat{I}^2$ -Mannosylceramide Presentation by CD1d. <i>Frontiers in Immunology</i> , 2019, 10, 2355.	2.2	5
23	Altered Lipid Tumor Environment and Its Potential Effects on NKT Cell Function in Tumor Immunity. <i>Frontiers in Immunology</i> , 2019, 10, 2187.	2.2	29
24	High-fidelity detection and sorting of nanoscale vesicles in viral disease and cancer. <i>Journal of Extracellular Vesicles</i> , 2019, 8, 1597603.	5.5	83
25	Myeloid Cell Crosstalk Regulates the Efficacy of the DNA/ALVAC/gp120 HIV Vaccine Candidate. <i>Frontiers in Immunology</i> , 2019, 10, 1072.	2.2	15
26	Interleukin 21 collaborates with interferon- $\hat{I}^3$ for the optimal expression of interferon-stimulated genes and enhances protection against enteric microbial infection. <i>PLoS Pathogens</i> , 2019, 15, e1007614.	2.1	10
27	The effect of antigen dose on T cell-targeting vaccine outcome. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 407-411.	1.4	36
28	Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response. <i>Journal of Clinical Investigation</i> , 2019, 129, 1314-1328.	3.9	28
29	IL13R $\hat{I}^2$ expression identifies tissue-resident IL $\hat{I}^2$ -producing PLZF <sup>+</sup> innate T cells in the human liver. <i>European Journal of Immunology</i> , 2018, 48, 1329-1335.	1.6	13
30	Plasma from some cancer patients inhibits adenoviral Ad5f35 vector transduction of dendritic cells. <i>Cytotherapy</i> , 2018, 20, 728-739.	0.3	4
31	Differential Regulation of T-cell mediated anti-tumor memory and cross-protection against the same tumor in lungs versus skin. <i>Oncolmunology</i> , 2018, 7, e1439305.	2.1	6
32	Effects of Cross-Presentation, Antigen Processing, and Peptide Binding in HIV Evasion of T Cell Immunity. <i>Journal of Immunology</i> , 2018, 200, ji1701523.	0.4	11
33	Cancer vaccines: translation from mice to human clinical trials. <i>Current Opinion in Immunology</i> , 2018, 51, 111-122.	2.4	39
34	Cancer vaccine strategies: translation from mice to human clinical trials. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1863-1869.	2.0	38
35	Tissue-Specific Roles of NKT Cells in Tumor Immunity. <i>Frontiers in Immunology</i> , 2018, 9, 1838.	2.2	87
36	Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. <i>Science</i> , 2018, 360, .	6.0	931

#	ARTICLE	IF	CITATIONS
37	Influence of gut microbiome on mucosal immune activation and SHIV viral transmission in naive macaques. <i>Mucosal Immunology</i> , 2018, 11, 1219-1229.	2.7	33
38	Possible Therapeutic Application of Targeting Type II Natural Killer T Cell-Mediated Suppression of Tumor Immunity. <i>Frontiers in Immunology</i> , 2018, 9, 314.	2.2	15
39	Prospective Use of High-Refractive Index Materials for Single Molecule Detection in Flow Cytometry. <i>Sensors</i> , 2018, 18, 2461.	2.1	12
40	Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2017, 23, 3352-3364.	3.2	24
41	Labeling Extracellular Vesicles for Nanoscale Flow Cytometry. <i>Scientific Reports</i> , 2017, 7, 1878.	1.6	260
42	Blockade of only TGF- $\beta$ 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy. <i>Oncolimmunology</i> , 2017, 6, e1308616.	2.1	71
43	Low Antigen Dose in Adjuvant-Based Vaccination Selectively Induces CD4 T Cells with Enhanced Functional Avidity and Protective Efficacy. <i>Journal of Immunology</i> , 2017, 198, 3494-3506.	0.4	57
44	Differential T cell homing to colon vs. small intestine is imprinted by local CD11c+ APCs that determine homing receptors. <i>Journal of Leukocyte Biology</i> , 2017, 102, 1381-1388.	1.5	13
45	Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity. <i>Cancer Immunology Research</i> , 2017, 5, 685-694.	1.6	37
46	Role of CD4 T $\beta$ cell helper subsets in immune response and deviation of CD8 T $\beta$ cells in mice*. <i>European Journal of Immunology</i> , 2017, 47, 2059-2069.	1.6	5
47	Association of autologous AdHER2 dendritic cell vaccination with antitumor activity and number of circulating tumor cells. <i>Journal of Clinical Oncology</i> , 2017, 35, 3089-3089.	0.8	4
48	Paradoxical myeloid-derived suppressor cell reduction in the bone marrow of SIV chronically infected macaques. <i>PLoS Pathogens</i> , 2017, 13, e1006395.	2.1	24
49	Early SIV Dissemination After Intrarectal SIVmac251 Challenge Was Associated With Proliferating Virus-Susceptible Cells in the Colorectum. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 353-358.	0.9	6
50	TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer. <i>Oncolimmunology</i> , 2016, 5, e1197459.	2.1	24
51	Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells. <i>Cancer Immunology Research</i> , 2016, 4, 354-365.	1.6	114
52	Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations. <i>Seminars in Oncology</i> , 2016, 43, 501-513.	0.8	10
53	Lack of the programmed death-1 receptor renders host susceptible to enteric microbial infection through impairing the production of the mucosal natural killer cell effector molecules. <i>Journal of Leukocyte Biology</i> , 2016, 99, 475-482.	1.5	20
54	NKT Cells in Tumor Immunity. , 2016, , 460-469.		2

#	ARTICLE	IF	CITATIONS
55	Tumor-induced CD11b <sup>+</sup> Gr <sup>1</sup> myeloid-derived suppressor cells exacerbate immune-mediated hepatitis in mice in a CD40-dependent manner. <i>European Journal of Immunology</i> , 2015, 45, 1148-1158.	1.6	10
56	Interleukin-15 Constrains Mucosal T Helper 17 Cell Generation: Influence of Mononuclear Phagocytes. <i>PLoS ONE</i> , 2015, 10, e0143001.	1.1	9
57	Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor $\beta^2$ by the monoclonal antibody fresolimumab (GC1008). <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 437-446.	2.0	104
58	Effect of TLR Agonists on the Differentiation and Function of Human Monocytic Myeloid-Derived Suppressor Cells. <i>Journal of Immunology</i> , 2015, 194, 4215-4221.	0.4	60
59	Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGF $\beta^2$ ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma. <i>PLoS ONE</i> , 2014, 9, e90353.	1.1	328
60	NKT Cell Networks in the Regulation of Tumor Immunity. <i>Frontiers in Immunology</i> , 2014, 5, 543.	2.2	110
61	Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaques. <i>Clinical Immunology</i> , 2014, 155, 91-107.	1.4	24
62	CD47 in the Tumor Microenvironment Limits Cooperation between Antitumor T-cell Immunity and Radiotherapy. <i>Cancer Research</i> , 2014, 74, 6771-6783.	0.4	179
63	Selective Inhibition of Regulatory T Cells by Targeting the PI3K/Akt Pathway. <i>Cancer Immunology Research</i> , 2014, 2, 1080-1089.	1.6	131
64	The immunoregulatory role of type I and type II NKT cells in cancer and other diseases. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 199-213.	2.0	71
65	Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses. <i>Clinical Immunology</i> , 2014, 153, 308-322.	1.4	20
66	Episomal Expression of Truncated Listeriolysin O in LmddA-LLO <sup>E7</sup> Vaccine Enhances Antitumor Efficacy by Preferentially Inducing Expansions of CD4 <sup>+</sup> FoxP3 <sup>+</sup> and CD8 <sup>+</sup> T Cells. <i>Cancer Immunology Research</i> , 2014, 2, 911-922.	1.6	35
67	Vaccine-induced myeloid cell population dampens protective immunity to SIV. <i>Journal of Clinical Investigation</i> , 2014, 124, 2538-2549.	3.9	58
68	Delicate Balance among Three Types of T Cells in Concurrent Regulation of Tumor Immunity. <i>Cancer Research</i> , 2013, 73, 1514-1523.	0.4	59
69	Balance is a key for happiness. <i>Oncot Immunology</i> , 2013, 2, e24211.	2.1	6
70	IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells. <i>Journal of Experimental Medicine</i> , 2013, 210, 491-502.	4.2	190
71	$\beta^2$ -Mannosylceramide Activates Type I Natural Killer T Cells to Induce Tumor Immunity without Inducing Long-Term Functional Anergy. <i>Clinical Cancer Research</i> , 2013, 19, 4404-4411.	3.2	15
72	Cancer vaccines: 21st century approaches to harnessing an ancient modality to fight cancer. <i>Expert Review of Vaccines</i> , 2013, 12, 1115-1118.	2.0	7

#	ARTICLE	IF	CITATIONS
73	Oral vaccines. <i>Gut Microbes</i> , 2013, 4, 246-252.	4.3	35
74	Identification and Enhancement of HLA-A2.1-Restricted CTL Epitopes in a New Human Cancer Antigen-POTE. <i>PLoS ONE</i> , 2013, 8, e64365.	1.1	15
75	A push-pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responses. <i>Vaccine</i> , 2012, 30, 4323-4327.	1.7	16
76	Improving Immunotherapy: Revisiting the Immunologist's Little Secret. <i>Science Translational Medicine</i> , 2012, 4, 120fs4.	5.8	3
77	Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection. <i>Nature Medicine</i> , 2012, 18, 1291-1296.	15.2	156
78	Strategies to Use Immune Modulators in Therapeutic Vaccines Against Cancer. <i>Seminars in Oncology</i> , 2012, 39, 348-357.	0.8	36
79	A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 373-384.	2.0	89
80	TLR agonists and/or IL-15 adjuvanted mucosal SIV vaccine reduced gut CD4+ memory T cell loss in SIVmac251-challenged rhesus macaques. <i>Vaccine</i> , 2011, 30, 59-68.	1.7	18
81	Mouse and human iNKT cell agonist Î²-mannosylceramide reveals a distinct mechanism of tumor immunity. <i>Journal of Clinical Investigation</i> , 2011, 121, 683-694.	3.9	41
82	Lack of IL-7 and IL-15 signaling affects interferon-Î³ production by, more than survival of, small intestinal intraepithelial memory CD8 <sup>+</sup> T cells. <i>European Journal of Immunology</i> , 2011, 41, 3513-3528.	1.6	7
83	KLF13 sustains thymic memory-like CD8 <sup>+</sup> T cells in BALB/c mice by regulating IL-4-generating invariant natural killer T cells. <i>Journal of Experimental Medicine</i> , 2011, 208, 1093-1103.	4.2	61
84	A Novel Combination Immunotherapy for Cancer by IL-13RÎ²2-Targeted DNA Vaccine and Immunotoxin in Murine Tumor Models. <i>Journal of Immunology</i> , 2011, 187, 4935-4946.	0.4	30
85	IL-15 ex vivo overcomes CD4 <sup>+</sup> T cell deficiency for the induction of human antigen-specific CD8 <sup>+</sup> T cell responses. <i>Journal of Leukocyte Biology</i> , 2011, 90, 205-214.	1.5	12
86	Blockade of TGF-Î² enhances tumor vaccine efficacy mediated by CD8 <sup>+</sup> T cells. <i>International Journal of Cancer</i> , 2010, 126, 1666-1674.	2.3	72
87	Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 9843-9848.	3.3	88
88	Multiple Antigen Peptide Vaccines against <i>Plasmodium falciparum</i> Malaria. <i>Infection and Immunity</i> , 2010, 78, 4613-4624.	1.0	53
89	Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. <i>Journal of Clinical Investigation</i> , 2010, 120, 607-616.	3.9	155
90	A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma. <i>Journal of Translational Medicine</i> , 2010, 8, 8.	1.8	29

#	ARTICLE	IF	CITATIONS
91	Use of Bioinformatics to Predict MHC Ligands and T-Cell Epitopes. <i>Methods in Microbiology</i> , 2010, 37, 35-66.	0.4	5
92	Pathogenic Roles of CD14, Galectin-3, and OX40 during Experimental Cerebral Malaria in Mice. <i>PLoS ONE</i> , 2009, 4, e6793.	1.1	34
93	Synergistic Enhancement of CD8+ T Cell-Mediated Tumor Vaccine Efficacy by an Anti-Transforming Growth Factor- $\beta$ Monoclonal Antibody. <i>Clinical Cancer Research</i> , 2009, 15, 6560-6569.	3.2	109
94	Unsung Hero Robert C. Gallo. <i>Science</i> , 2009, 323, 206-207.	6.0	2
95	The Contrasting Roles of NKT Cells in Tumor Immunity. <i>Current Molecular Medicine</i> , 2009, 9, 667-672.	0.6	90
96	Natural immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 907-912.	2.0	29
97	A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1679-1683.	2.0	50
98	Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies. <i>European Journal of Immunology</i> , 2008, 38, 1706-1720.	1.6	50
99	Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization. <i>Virology</i> , 2008, 381, 106-115.	1.1	50
100	Estimation of low frequency antigen-presenting cells with a novel RELISPOT assay. <i>Journal of Immunological Methods</i> , 2008, 333, 71-78.	0.6	2
101	Commensal DNA Limits Regulatory T Cell Conversion and Is a Natural Adjuvant of Intestinal Immune Responses. <i>Immunity</i> , 2008, 29, 637-649.	6.6	446
102	Regulation of tumor immunity: the role of NKT cells. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 725-734.	1.4	26
103	Chapter 8 The Role of NKT Cells in Tumor Immunity. <i>Advances in Cancer Research</i> , 2008, 101, 277-348.	1.9	274
104	Restoration of Tumor Immunosurveillance via Targeting of Interleukin-13 Receptor- $\beta$ 2. <i>Cancer Research</i> , 2008, 68, 3467-3475.	0.4	81
105	NKT Cells in Tumor Immunity: Opposing Subsets Define a New Immunoregulatory Axis. <i>Journal of Immunology</i> , 2008, 180, 3627-3635.	0.4	115
106	An Anti-Transforming Growth Factor $\beta$ Antibody Suppresses Metastasis via Cooperative Effects on Multiple Cell Compartments. <i>Cancer Research</i> , 2008, 68, 3835-3843.	0.4	203
107	IL-15 Expands Unconventional CD8 $\beta$ 1 $\beta$ NK1.1+ T Cells but Not V $\beta$ 14 $\beta$ 18+ NKT Cells. <i>Journal of Immunology</i> , 2008, 180, 7276-7286.	0.4	22
108	Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: Implications for vaccines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 16260-16265.	3.3	155

#	ARTICLE	IF	CITATIONS
109	IL-15 as a mediator of CD4 help for CD8 T cell longevity and avoidance of TRAIL-mediated apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5201-5206.	3.3	128
110	A Pilot Study of Consolidative Immunotherapy in Patients with High-Risk Pediatric Sarcomas. Clinical Cancer Research, 2008, 14, 4850-4858.	3.2	142
111	Transforming Growth Factor $\beta$ 2 Subverts the Immune System into Directly Promoting Tumor Growth through Interleukin-17. Cancer Research, 2008, 68, 3915-3923.	0.4	233
112	Therapy of Advanced Established Murine Breast Cancer with a Recombinant Adenoviral ErbB-2/neu Vaccine. Cancer Research, 2008, 68, 1979-1987.	0.4	38
113	Development of Smallpox Vaccine Candidates with Integrated Interleukin-15 That Demonstrate Superior Immunogenicity, Efficacy, and Safety in Mice. Journal of Virology, 2007, 81, 8774-8783.	1.5	38
114	A Novel Functional CTL Avidity/Activity Compartmentalization to the Site of Mucosal Immunization Contributes to Protection of Macaques against Simian/Human Immunodeficiency Viral Depletion of Mucosal CD4+ T Cells. Journal of Immunology, 2007, 178, 7211-7221.	0.4	93
115	Role of $\beta$ 3 domain of class I MHC molecules in the activation of high- and low-avidity CD8+ CTLs. International Immunology, 2007, 19, 1413-1420.	1.8	7
116	Hemagglutinin Protein Is a Primary Target of the Measles Virus-Specific HLA-A2-Restricted CD8+ T Cell Response during Measles and after Vaccination. Journal of Infectious Diseases, 2007, 195, 1799-1807.	1.9	34
117	Avidity of CD8 T cells sharpens immunodominance. International Immunology, 2007, 19, 497-507.	1.8	38
118	Cross-Regulation between Type I and Type II NKT Cells in Regulating Tumor Immunity: A New Immunoregulatory Axis. Journal of Immunology, 2007, 179, 5126-5136.	0.4	187
119	Impact of vaccine-induced mucosal high-avidity CD8+CTLs in delay of AIDS viral dissemination from mucosa. Blood, 2006, 107, 3258-3264.	0.6	127
120	Combined prophylactic and therapeutic cancer vaccine: Enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice. International Journal of Cancer, 2006, 118, 3022-3029.	2.3	28
121	Characterization of a Novel Human Tumor Antigen Interleukin-13 Receptor $\beta$ 2 Chain. Cancer Research, 2006, 66, 4434-4442.	0.4	29
122	Systemic Immunization with an ALVAC-HIV-1/Protein Boost Vaccine Strategy Protects Rhesus Macaques from CD4 + T-Cell Loss and Reduces both Systemic and Mucosal Simian-Human Immunodeficiency Virus SHIV KU2 RNA Levels. Journal of Virology, 2006, 80, 3732-3742.	1.5	67
123	Identification and Epitope Enhancement of a PAX-FKHR Fusion Protein Breakpoint Epitope in Alveolar Rhabdomyosarcoma Cells Created by a Tumorigenic Chromosomal Translocation Inducing CTL Capable of Lysing Human Tumors. Cancer Research, 2006, 66, 1818-1823.	0.4	37
124	Persistent Human Papillomavirus Infection Is Associated with a Generalized Decrease in Immune Responsiveness in Older Women. Cancer Research, 2006, 66, 11070-11076.	0.4	98
125	CD1d-Restricted Natural Killer T Cells Can Down-regulate Tumor Immunosurveillance Independent of Interleukin-4 Receptor-Signal Transducer and Activator of Transcription 6 or Transforming Growth Factor- $\beta$ 2. Cancer Research, 2006, 66, 3869-3875.	0.4	54
126	The NS2 Protein of Human Respiratory Syncytial Virus Suppresses the Cytotoxic T-Cell Response as a Consequence of Suppressing the Type I Interferon Response. Journal of Virology, 2006, 80, 5958-5967.	1.5	39



#	ARTICLE	IF	CITATIONS
127	Enhancement of CD8+ T Cell Immunity in the Lung by CpG Oligodeoxynucleotides Increases Protective Efficacy of a Modified Vaccinia Ankara Vaccine against Lethal Poxvirus Infection Even in a CD4-Deficient Host. <i>Journal of Immunology</i> , 2006, 177, 6336-6343.	0.4	42
128	Epitope Enhancement of a CD4 HIV Epitope toward the Development of the Next Generation HIV Vaccine. <i>Journal of Immunology</i> , 2006, 176, 3753-3759.	0.4	15
129	Intratumoral Therapy with IL13-PE38 Results in Effective CTL-Mediated Suppression of IL-13 $\beta$ -Expressing Contralateral Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 4678-4686.	3.2	20
130	Possible Therapeutic Vaccine Strategy against Human Immunodeficiency Virus Escape from Reverse Transcriptase Inhibitors Studied in HLA-A2 Transgenic Mice. <i>Journal of Virology</i> , 2006, 80, 10645-10651.	1.5	12
131	Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. <i>Nature Medicine</i> , 2005, 11, 1238-1243.	15.2	366
132	Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13. <i>International Journal of Cancer</i> , 2005, 114, 80-87.	2.3	88
133	Immunization With Mutant p53- and K-ras $\alpha$ -Derived Peptides in Cancer Patients: Immune Response and Clinical Outcome. <i>Journal of Clinical Oncology</i> , 2005, 23, 5099-5107.	0.8	167
134	Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. <i>Journal of Experimental Medicine</i> , 2005, 201, 139-148.	4.2	636
135	Expression of Interleukin-4 by Recombinant Respiratory Syncytial Virus Is Associated with Accelerated Inflammation and a Nonfunctional Cytotoxic T-Lymphocyte Response following Primary Infection but Not following Challenge with Wild-Type Virus. <i>Journal of Virology</i> , 2005, 79, 9515-9526.	1.5	26
136	Early Role of CD4+ Th1 Cells and Antibodies in HER-2 Adenovirus Vaccine Protection against Autochthonous Mammary Carcinomas. <i>Journal of Immunology</i> , 2005, 174, 4228-4236.	0.4	80
137	A nonclassical non-V $\beta$ 14J $\beta$ 18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. <i>Journal of Experimental Medicine</i> , 2005, 202, 1627-1633.	4.2	262
138	Selecting stable molecular targets for treatment and prevention of AIDS. <i>Genome Informatics</i> , 2005, 16, 254-61.	0.4	1
139	Human CTLs to Wild-Type and Enhanced Epitopes of a Novel Prostate and Breast Tumor-Associated Protein, TARP, Lyse Human Breast Cancer Cells. <i>Cancer Research</i> , 2004, 64, 2610-2618.	0.4	70
140	IL-15/IL-15R $\alpha$ -mediated avidity maturation of memory CD8+ T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 15154-15159.	3.3	123
141	Protection against Lethal Vaccinia Virus Challenge in HLA-A2 Transgenic Mice by Immunization with a Single CD8 + T-Cell Peptide Epitope of Vaccinia and Variola Viruses. <i>Journal of Virology</i> , 2004, 78, 7052-7060.	1.5	101
142	Vaccination by Genetically Modified Dendritic Cells Expressing a Truncated neu Oncogene Prevents Development of Breast Cancer in Transgenic Mice. <i>Cancer Research</i> , 2004, 64, 8022-8028.	0.4	86
143	Immunoregulatory T cells in tumor immunity. <i>Current Opinion in Immunology</i> , 2004, 16, 157-162.	2.4	237
144	Role of IL-13 in regulation of anti-tumor immunity and tumor growth. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 79-85.	2.0	181

#	ARTICLE	IF	CITATIONS
145	Non-Hodgkin's lymphoma among asthmatics exposed to pesticides. <i>International Journal of Cancer</i> , 2004, 111, 298-302.	2.3	34
146	Mucosal AIDS vaccines: current status and future directions. <i>Expert Review of Vaccines</i> , 2004, 3, S65-S73.	2.0	30
147	Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. <i>Journal of Clinical Investigation</i> , 2004, 113, 998-1007.	3.9	182
148	Immunobiology of Mucosal HIV Infection and the Basis for Development of a New Generation of Mucosal AIDS Vaccines. <i>Immunity</i> , 2004, 20, 247-253.	6.6	125
149	Progress on new vaccine strategies for the immunotherapy and prevention of cancer. <i>Journal of Clinical Investigation</i> , 2004, 113, 1515-1525.	3.9	175
150	Progress on new vaccine strategies against chronic viral infections. <i>Journal of Clinical Investigation</i> , 2004, 114, 450-462.	3.9	68
151	Dendritic Cell-Induced Activation of Adaptive and Innate Antitumor Immunity. <i>Journal of Immunology</i> , 2003, 171, 5842-5852.	0.4	87
152	Cellular Immune Responses to Human Papillomavirus (HPV) 16 L1 in Healthy Volunteers Immunized with Recombinant HPV 16 L1 Virus-Like Particles. <i>Journal of Infectious Diseases</i> , 2003, 188, 327-338.	1.9	159
153	Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 3392-3397.	3.3	174
154	Selective Induction of High Avidity CTL by Altering the Balance of Signals from APC. <i>Journal of Immunology</i> , 2003, 170, 2523-2530.	0.4	120
155	Transforming Growth Factor- $\beta$ 2 Production and Myeloid Cells Are an Effector Mechanism through Which CD1d-restricted T Cells Block Cytotoxic T Lymphocyte-mediated Tumor Immunosurveillance. <i>Journal of Experimental Medicine</i> , 2003, 198, 1741-1752.	4.2	508
156	Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 9458-9463.	3.3	263
157	Epitope-Enhanced Conserved HIV-1 Peptide Protects HLA-A2-Transgenic Mice Against Virus Expressing HIV-1 Antigen. <i>Journal of Immunology</i> , 2003, 171, 2548-2555.	0.4	33
158	Molecular Mechanisms and Biological Significance of CTL Avidity. <i>Current HIV Research</i> , 2003, 1, 287-294.	0.2	71
159	Cytokine, Chemokine, and Costimulatory Molecule Modulation to Enhance Efficacy of HIV Vaccines. <i>Current Molecular Medicine</i> , 2003, 3, 285-301.	0.6	75
160	Effects of Cytotoxic T Lymphocytes (CTL) Directed against a Single Simian Immunodeficiency Virus (SIV) Gag CTL Epitope on the Course of SIVmac239 Infection. <i>Journal of Virology</i> , 2002, 76, 10507-10511.	1.5	52
161	Use of bioinformatics to predict MHC ligands and T-cell epitopes: Application to epitope-driven vaccine design. <i>Methods in Microbiology</i> , 2002, 32, 99-123.	0.4	1
162	Resistance to Metastatic Disease in STAT6-Deficient Mice Requires Hemopoietic and Nonhemopoietic Cells and Is IFN- $\beta$ Dependent. <i>Journal of Immunology</i> , 2002, 169, 5796-5804.	0.4	109

#	ARTICLE	IF	CITATIONS
163	A push-pull approach to maximize vaccine efficacy: Abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13020-13025.	3.3	89
164	Rapid Induction of Apoptosis in CD8+ HIV-1 Envelope-Specific Murine CTLs by Short Exposure to Antigenic Peptide. Journal of Immunology, 2002, 169, 6588-6593.	0.4	25
165	DNA vaccines encoding human immunodeficiency virus gp120 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood, 2002, 100, 1153-1159.	0.6	127
166	Definition of T cell epitopes within the 19 kDa carboxylterminal fragment of Plasmodium yoelii merozoite surface protein 1 (MSP119) and their role in immunity to malaria. Parasite Immunology, 2002, 20, 263-278.	0.7	28
167	Clinical Trial Designs for the Early Clinical Development of Therapeutic Cancer Vaccines. Journal of Clinical Oncology, 2001, 19, 1848-1854.	0.8	113
168	An abrupt and concordant initiation of apoptosis: antigen-dependent death of CD8+ CTL. European Journal of Immunology, 2001, 31, 2951-2959.	1.6	27
169	Impaired development of HIV-1 gp160-specific CD8+ cytotoxic T cells by a delayed switch from Th1 to Th2 cytokine phenotype in mice with Helicobacter pylori infection. European Journal of Immunology, 2001, 31, 516-526.	1.6	2
170	Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. International Immunology, 2001, 13, 897-908.	1.8	73
171	Mice infected with Schistosoma mansoni develop a novel non-T-lymphocyte suppressor population which inhibits virus-specific CTL induction via a soluble factor. Microbes and Infection, 2001, 3, 1051-1061.	1.0	27
172	Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nature Medicine, 2001, 7, 1320-1326.	15.2	231
173	Strategies for designing and optimizing new generation vaccines. Nature Reviews Immunology, 2001, 1, 209-219.	10.6	319
174	Competitive Inhibition In Vivo and Skewing of the T Cell Repertoire of Antigen-Specific CTL Priming by an Anti-Peptide-MHC Monoclonal Antibody. Journal of Immunology, 2001, 167, 699-707.	0.4	8
175	Two intermediate-avidity cytotoxic T lymphocyte clones with a disparity between functional avidity and MHC tetramer staining. International Immunology, 2001, 13, 817-824.	1.8	61
176	High-Avidity CTL Exploit Two Complementary Mechanisms to Provide Better Protection Against Viral Infection Than Low-Avidity CTL. Journal of Immunology, 2001, 166, 1690-1697.	0.4	196
177	Immunostimulatory DNA-Based Vaccines Elicit Multifaceted Immune Responses Against HIV at Systemic and Mucosal Sites. Journal of Immunology, 2001, 167, 1584-1591.	0.4	100
178	Counter-regulation of cytolytic activity and cytokine production in HIV-1-specific murine CD8+ cytotoxic T lymphocytes by free antigenic peptide. International Immunology, 2001, 13, 43-51.	1.8	6
179	Signals delivered through TCR instruct IL-12 receptor (IL-12R) expression: IL-12 and tumor necrosis factor- $\alpha$ synergize for IL-12R expression at low antigen dose. International Immunology, 2001, 13, 1433-1442.	1.8	25
180	Impairment of Gag-Specific CD8 + T-Cell Function in Mucosal and Systemic Compartments of Simian Immunodeficiency Virus mac251- and Simian-Human Immunodeficiency Virus KU2-Infected Macaques. Journal of Virology, 2001, 75, 11483-11495.	1.5	67

#	ARTICLE	IF	CITATIONS
181	Rabies Virus-Based Vectors Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Protein Induce a Strong, Cross-Reactive Cytotoxic T-Lymphocyte Response against Envelope Proteins from Different HIV-1 Isolates. <i>Journal of Virology</i> , 2001, 75, 4430-4434.	1.5	59
182	Granulocyte-Macrophage Colony-Stimulating Factor Expressed by Recombinant Respiratory Syncytial Virus Attenuates Viral Replication and Increases the Level of Pulmonary Antigen-Presenting Cells. <i>Journal of Virology</i> , 2001, 75, 12128-12140.	1.5	74
183	High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection. <i>Journal of Clinical Investigation</i> , 2001, 108, 1677-1685.	3.9	72
184	Semi-allogeneic cell hybrids stimulate HIV-1 envelope-specific cytotoxic T lymphocytes. <i>Aids</i> , 2000, 14, 1497-1506.	1.0	11
185	NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4/STAT6 pathway. <i>Nature Immunology</i> , 2000, 1, 515-520.	7.0	639
186	Antibodies Directed Against the MHC-I Molecule H-2Dd Complexed with an Antigenic Peptide: Similarities to a T Cell Receptor with the Same Specificity. <i>Journal of Immunology</i> , 2000, 165, 5703-5712.	0.4	29
187	Characterization of Conserved T- and B-Cell Epitopes in Plasmodium falciparum Major Merozoite Surface Protein 1. <i>Infection and Immunity</i> , 2000, 68, 2685-2691.	1.0	26
188	Interplay of Cytokines and Adjuvants in the Regulation of Mucosal and Systemic HIV-Specific CTL. <i>Journal of Immunology</i> , 2000, 165, 6454-6462.	0.4	85
189	HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. <i>Aids</i> , 1999, 13, 2003-2012.	1.0	44
190	Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections. <i>Immunological Reviews</i> , 1999, 170, 151-172.	2.8	94
191	Effect of Zidovudine Postexposure Prophylaxis on the Development of HIV-Specific Cytotoxic T-Lymphocyte Responses in HIV-Exposed Healthcare Workers. <i>Infection Control and Hospital Epidemiology</i> , 1999, 20, 428-430.	1.0	17
192	Supraoptimal Peptide-Major Histocompatibility Complex Causes a Decrease in Bcl-2 Levels and Allows Tumor Necrosis Factor $\alpha$ Receptor-mediated Apoptosis of Cytotoxic T Lymphocytes. <i>Journal of Experimental Medicine</i> , 1998, 188, 1391-1399.	4.2	89
193	Molecular Alterations in Pediatric Sarcomas: Potential Targets for Immunotherapy. <i>Sarcoma</i> , 1998, 2, 77-87.	0.7	18
194	Induction of a Mucosal Cytotoxic T-Lymphocyte Response by Intrarectal Immunization with a Replication-Deficient Recombinant Vaccinia Virus Expressing Human Immunodeficiency Virus 89.6 Envelope Protein. <i>Journal of Virology</i> , 1998, 72, 8264-8272.	1.5	105
195	Target Cell Lysis by CTL Granule Exocytosis Is Independent of ICE/Ced-3 Family Proteases. <i>Immunity</i> , 1997, 6, 209-215.	6.6	210
196	Cytotoxic T lymphocyte (CTL) adherence assay (CAA): a non-radioactive assay for murine CTL recognition of peptide-MHC class I complexes. <i>Journal of Immunological Methods</i> , 1997, 201, 1-10.	0.6	4
197	Structural comparison of a 15 residue peptide from the V3 loop of HIV-1IIIB and an O-glycosylated analogue. <i>FEBS Letters</i> , 1996, 393, 280-286.	1.3	35
198	Dendritic Cells in Antitumor Immune Responses. <i>Cellular Immunology</i> , 1996, 170, 111-119.	1.4	199

#	ARTICLE	IF	CITATIONS
199	Prediction of HIV Peptide Epitopes by a Novel Algorithm. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 593-610.	0.5	41
200	Candidate HIV Type 1 Multideterminant Cluster Peptide-P18MN Vaccine Constructs Elicit Type 1 Helper T Cells, Cytotoxic T Cells, and Neutralizing Antibody, All Using the Same Adjuvant Immunization. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 259-272.	0.5	49
201	Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-1 envelope protein to human cytotoxic T lymphocytes. <i>International Immunology</i> , 1996, 8, 641-649.	1.8	33
202	Designing Peptide Vaccines to Broaden Recognition and Enhance Potency. <i>Annals of the New York Academy of Sciences</i> , 1995, 754, 161-168.	1.8	24
203	Binding of Glycoprotein 120 and Peptides from the HIV-1 Envelope by Autoantibodies in Mice with Experimentally Induced Systemic Lupus Erythematosus and in Patients with the Disease. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 1071-1077.	0.5	29
204	Increased susceptibility of mice infected with <i>Schistosoma mansoni</i> to recombinant vaccinia virus: Association of viral persistence with egg granuloma formation. <i>European Journal of Immunology</i> , 1994, 24, 3050-3056.	1.6	52
205	Minimal requirements for peptide mediated activation of CD8+ CTL. <i>Molecular Immunology</i> , 1994, 31, 1285-1293.	1.0	66
206	Sequence features that correlate with MHC restriction. <i>Molecular Immunology</i> , 1994, 31, 1-19.	1.0	34
207	FcÎµ receptor-positive cells are a major source of antigen-induced interleukin-4 in spleens of mice infected with <i>Schistosoma mansoni</i> . <i>European Journal of Immunology</i> , 1993, 23, 1910-1916.	1.6	54
208	Epitope Selection and Design of Synthetic Vaccines Molecular Approaches to Enhancing Immunogenicity and Cross-Reactivity of Engineered Vaccines. <i>Annals of the New York Academy of Sciences</i> , 1993, 690, 256-264.	1.8	48
209	Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. <i>International Immunology</i> , 1993, 5, 849-857.	1.8	142
210	Role of conserved regions of class I MHC molecules in the activation of CD8+ cytotoxic T lymphocytes by peptide and purified cell-free class I molecules. <i>International Immunology</i> , 1993, 5, 1129-1138.	1.8	17
211	Cell-Mediated Immune Response to Human Immunodeficiency Virus (HIV) Type 1 in Seronegative Homosexual Men with Recent Sexual Exposure to HIV-1. <i>Journal of Infectious Diseases</i> , 1992, 165, 1012-1019.	1.9	396
212	Role of T-Cell Derived Cytokines in the Downregulation of Immune Responses in Parasitic and Retroviral Infection. <i>Immunological Reviews</i> , 1992, 127, 183-204.	2.8	484
213	Mechanisms of T cell recognition with application to vaccine design. <i>Molecular Immunology</i> , 1991, 28, 217-223.	1.0	19
214	Development of artificial vaccines against HIV using defined epitopes. <i>FASEB Journal</i> , 1991, 5, 2412-2418.	0.2	54
215	Excess Î²2 microglobulin promoting functional peptide association with purified soluble class I MHC molecules. <i>Nature</i> , 1991, 349, 74-77.	13.7	128
216	Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection. <i>European Journal of Immunology</i> , 1991, 21, 1345-1349.	1.6	45

#	ARTICLE	IF	CITATIONS
217	Different B-cell responses to human T-cell lymphotropic virus type I (HTLV-I) envelope synthetic peptides in HTLV-I-infected individuals. <i>Journal of Clinical Immunology</i> , 1991, 11, 143-151.	2.0	10
218	Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. <i>Nature</i> , 1990, 344, 873-875.	13.7	505
219	Repeated determinants within the retinal interphotoreceptor retinoid-binding protein (IRBP): Immunological properties of the repeats of an immunodominant determinant. <i>Cellular Immunology</i> , 1990, 126, 331-342.	1.4	18
220	Characterization of a helper T cell epitope recognized by mice of a low responder major histocompatibility type. <i>Molecular Immunology</i> , 1990, 27, 941-946.	1.0	5
221	[40] Identification of T-cell epitopes and use in construction of synthetic vaccines. <i>Methods in Enzymology</i> , 1989, 178, 611-634.	0.4	29
222	Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals. <i>Nature</i> , 1989, 339, 383-385.	13.7	232
223	Immune responses to peptides derived from the retinal protein IRBP: Immunopathogenic determinants are not necessarily immunodominant. <i>Clinical Immunology and Immunopathology</i> , 1989, 53, 212-224.	2.1	15
224	Immunodominance in T lymphocyte recognition. <i>Immunology Letters</i> , 1988, 18, 83-92.	1.1	73
225	Antigen Processing for Presentation to T Lymphocytes: Function, Mechanisms, and Implications for the T-Cell Repertoire. <i>Immunological Reviews</i> , 1988, 106, 5-31.	2.8	107
226	Cytotoxic T cells specific for the circumsporozoite protein of <i>Plasmodium falciparum</i> . <i>Nature</i> , 1988, 334, 258-260.	13.7	201
227	Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. <i>Nature</i> , 1988, 334, 706-708.	13.7	158
228	Antigenic structures recognized by T cells. <i>Aids</i> , 1988, 2, S95-102.	1.0	11
229	<i>Plasmodium falciparum</i> : Sporozoite boosting of immunity due to a T-cell epitope on a sporozoite vaccine. <i>Experimental Parasitology</i> , 1987, 64, 64-70.	0.5	27
230	Hydrophobicity scales and computational techniques for detecting amphipathic structures in proteins. <i>Journal of Molecular Biology</i> , 1987, 195, 659-685.	2.0	627
231	Cloned protein antigen-specific, Ia-restricted T cells with both helper and cytolytic activities: Mechanisms of activation and killing. <i>Cellular Immunology</i> , 1987, 105, 301-316.	1.4	48
232	Protein Antigenic Structures Recognized by T Cells; Potential Applications to Vaccine Design. <i>Immunological Reviews</i> , 1987, 98, 9-52.	2.8	144
233	Myoglobin adsorption onto crosslinked polydimethylsiloxane. <i>Journal of Colloid and Interface Science</i> , 1986, 111, 466-474.	5.0	21
234	How many class II immune response genes? A reappraisal of the evidence. <i>Immunogenetics</i> , 1986, 23, 302-308.	1.2	13

#	ARTICLE	IF	CITATIONS
235	CORRELATION OF INTRATHYMIC TOLERANCE WITH INTRATHYMIC CHIMERISM IN NEONATALLY TOLERIZED MICE. Transplantation, 1985, 40, 68-72.	0.5	30
236	A unidirectional carrier effect. Cellular Immunology, 1985, 92, 226-234.	1.4	1
237	An Ia-restricted epitope-specific circuit regulating T cell-B cell interaction and antibody specificity. Survey of Immunologic Research, 1983, 2, 223-229.	0.4	71
238	Genetic control of the immune response to staphylococcal nuclease. Seminars in Immunopathology, 1978, 1, 51-83.	4.0	33
239	Studies on oxidative drug metabolism in the full-term newborn infant. Journal of Pediatrics, 1966, 69, 1139-1149.	0.9	30